This proposal is to support the participation of the City of Hope National Medical Center in the investigational clinical trials of the Southwest Oncology Group (SWOG). SWOG members at City of Hope will provide scientific input into pilot protocol development, group-wide phase II and phase III protocol development, pharmacology trials and biological response modifier protocols. In addition, SWOG members from the City of Hope will participate heavily in research activities in solid tumor chemotherapy, oncologic surgery, hematologic malignancy, bone marrow transplantation, radiation oncology and hyperthermia, and surgical pathology. By participation of the City of Hope in SWOG clinical research, the rate of completion of high quality, multimodality clinical trials will be increased and innovative treatment concepts devised by the SWOG and the City of Hope will become more widely available in Soutern California. The participation of the City of Hope in previous cooperative group studies has been at the rate of 75 patients per year in the absence of active studies in leukemia in the Northern California Oncology Group. With the availability of new bone marrow transplantation protocols chaired by City of Hope investigators and an active leukemia committee, accrual to SWOG studies at the City of Hope should increase to 90-100 patients per year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA046368-01
Application #
3558748
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-01-01
Project End
1992-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769

Showing the most recent 10 out of 153 publications